These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32918576)

  • 1. Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression.
    Elkilany A; Geisel D; Müller T; Fischer A; Denecke T
    Abdom Radiol (NY); 2021 Mar; 46(3):979-991. PubMed ID: 32918576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis.
    Schulze J; Lenzen H; Hinrichs JB; Ringe B; Manns MP; Wacker F; Ringe KI
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):192-199.e3. PubMed ID: 29775791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total Bilirubin Level as a Predictor of Suboptimal Image Quality of the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI in Patients with Extrahepatic Bile Duct Cancer.
    Hwang JA; Min JH; Kim SH; Choi SY; Lee JE; Moon JY
    Korean J Radiol; 2022 Apr; 23(4):389-401. PubMed ID: 35029076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary sclerosing cholangitis: diagnostic performance of MRI compared to blood tests and clinical scoring systems for the evaluation of histopathological severity of disease.
    Song C; Lewis S; Kamath A; Hectors S; Putra J; Kihira S; Bane O; Ahmad J; Babb J; Thung S; Taouli B
    Abdom Radiol (NY); 2020 Feb; 45(2):354-364. PubMed ID: 31844914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary tract enhancement in gadoxetic acid-enhanced MRI correlates with liver function biomarkers.
    Noda Y; Goshima S; Kajita K; Kawada H; Kawai N; Koyasu H; Matsuo M; Bae KT
    Eur J Radiol; 2016 Nov; 85(11):2001-2007. PubMed ID: 27776652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis.
    Petrovic BD; Nikolaidis P; Hammond NA; Martin JA; Petrovic PV; Desai PM; Miller FH
    Dig Dis Sci; 2007 Dec; 52(12):3499-506. PubMed ID: 17410447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.
    Beer L; Mandorfer M; Bastati N; Poetter-Lang S; Tamandl D; Stoyanova DP; Elmer MC; Semmler G; Simbrunner B; Hodge JC; Sirlin CB; Reiberger T; Ba-Ssalamah A
    Eur Radiol; 2019 Dec; 29(12):6600-6610. PubMed ID: 31001679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC).
    Hinrichs H; Hinrichs JB; Gutberlet M; Lenzen H; Raatschen HJ; Wacker F; Ringe KI
    Eur Radiol; 2016 Apr; 26(4):1116-24. PubMed ID: 26205638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture.
    Poetter-Lang S; Ba-Ssalamah A; Messner A; Bastati N; Ambros R; Kristic A; Kittinger J; Pochepnia S; Ba-Ssalamah SA; Hodge JC; Halilbasic E; Venkatesh SK; Kartalis N; Ringe K; Arrivé L; Trauner M
    Eur Radiol; 2024 Jun; ():. PubMed ID: 38869640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes.
    Bookwalter CA; Venkatesh SK; Eaton JE; Smyrk TD; Ehman RL
    Abdom Radiol (NY); 2018 Dec; 43(12):3260-3270. PubMed ID: 29626258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography.
    Nolz R; Asenbaum U; Schoder M; Wibmer A; Einspieler H; Prusa AM; Peck-Radosavljevic M; Ba-Ssalamah A
    Clin Radiol; 2014 May; 69(5):499-508. PubMed ID: 24630133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis.
    Lemoinne S; Cazzagon N; El Mouhadi S; Trivedi PJ; Dohan A; Kemgang A; Ben Belkacem K; Housset C; Chretien Y; Corpechot C; Hirschfield G; Floreani A; Motta R; Gallix B; Barkun A; Barkun J; Chazouillères O; Arrivé L
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2785-2792.e3. PubMed ID: 30880273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis.
    Tenca A; Mustonen H; Lind K; Lantto E; Kolho KL; Boyd S; Arola J; Jokelainen K; Färkkilä M
    Liver Int; 2018 Dec; 38(12):2329-2339. PubMed ID: 29901259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.
    Ringe KI; Hinrichs J; Merkle EM; Weismüller TJ; Wacker F; Meyer BC
    J Magn Reson Imaging; 2014 Jul; 40(1):106-12. PubMed ID: 24923477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of the gadoxetic acid MRI-derived relative enhancement index (REI) and functional liver imaging score (FLIS) in predicting liver function: validation with Albumin-Bilirubin (ALBI) grade.
    Eryuruk U; Tasdemir MN; Karasu HI; Aslan S
    Abdom Radiol (NY); 2024 May; 49(5):1456-1466. PubMed ID: 38653813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating hepatotoxic effects of chemotherapeutic agents with gadoxetic-acid-enhanced magnetic resonance imaging.
    Theilig D; Elkilany A; Jann H; Roderburg C; Hamm B; Fehrenbach U; Geisel D
    Eur J Radiol; 2020 Mar; 124():108807. PubMed ID: 31926386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC).
    Ringe KI; Bergquist A; Lenzen H; Kartalis N; Manns MP; Wacker F; Grigoriadis A
    Eur J Radiol; 2020 Aug; 129():109101. PubMed ID: 32505896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.
    Verloh N; Haimerl M; Zeman F; Schlabeck M; Barreiros A; Loss M; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
    Eur Radiol; 2014 May; 24(5):1013-9. PubMed ID: 24531844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.